The battle in ZIOP continues to rage-RJ Kirk vs. the short. One way or the other in the next 30-45 days as they either ink a deal or do yet another financing round. ZIOP has make or break PHIII data in STS coming out Q4 and must do something PRIOR to solidify the balance sheet in the case of a miss. My bet remains 1) a deal and 2)good STS data in that order followed up by news in breast and/or synthetics. The balance of 2012 should be very interesting for this small molecule turned synthetic biology oncology drug developer.
Kirk needs a win following HALO mis-fire. His ultimate goal is to prove validity of Intrexon platform and IPO his crown jewel.
Shorts remain committed with 10MM share negative bet. Some of this is likely wt. related.
Disclosure: I am long ZIOP.